Associação Brasileira de Hematologia, Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Review article: Cell therapy in solid tumors

Nardo, Mirella; Motta, Tatiane Cardoso; Colli, Leandro M.; Avanzi, Mauro P.

doi:10.1016/j.htct.2021.09.011

Cited by 2 publications

(5 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Os resultados de diferentes estudos sugerem que o TCTH alogênico pode curar até 50% a 60% dos receptores, que não atingiriam tal resultado somente com quimioterapia. A busca por um doador compatível no transplante alogênico pode dificultar e tornar mais tardio o tratamento, já que apenas 30% dos pacientes terão um doador compatível (MORANDO et al,2010;ALMEIDA, et al, 2021).…”

Section: Referencial Teóricounclassified

“…Em um estudo realizado em instituições brasileiras entre 1990 e 2007 com 119 pacientes diagnosticados com leucemia linfóide aguda mostrou que a sobrevida global para esses pacientes foi de 43% em três anos. E ainda, os resultados mostraram que aqueles pacientes condicionados com irradiação corporal total obtiveram menor incidência de recidiva (MORANDO, et al, 2010).…”

Section: Referencial Teóricounclassified

“…O TCTH é utilizado quando os tratamentos convencionais não são eficazes (LIMA et al, 2018) e quando apresentam maior risco de recaídas (MORANDO et al, 2010). Em 2017, mais 40.000 pessoas realizaram esse transplante no Brasil (LIMA et al, 2018).…”

Section: Introductionunclassified

See 2 more Smart Citations

Tratamento da leucemia linfóide aguda em crianças: uma revisão narrativa

Weber¹,

Carrijo²,

Pereira³

et al. 2023

Braz. J. Develop.

View full text Add to dashboard Cite

A Leucemia Linfoide Aguda (LLA) é uma neoplasia caracterizada por uma proliferação de linfoides primitivos. É mais comum na infância com um maior predomínio antes dos 5 anos de idade e representa o décimo câncer mais comum no Brasil. O objetivo desse trabalho é o entendimento das manifestações da doença e seus tratamentos, além de mostrar uma nova terapia que tem uma significativa promessa para o futuro do tratamento da LLA. São discutidos ao longo deste trabalho os sinais clínicos e diagnóstico da leucemia. E ainda, descrito os métodos diagnósticos e tratamentos que podem ser realizados, com suas principais indicações e efeitos adversos. Esta pesquisa surge a partir de uma revisão bibliográfica, baseando em publicações cientificas dos últimos 12 anos, realizada através da busca bibliográfica nos bancos de dados PubMed, Scielo, Google Acadêmico, Biblioteca Virtual em Saúde (BVS) e Portal Capes. Conclui-se que a LLA é uma neoplasia com evolução rápida e que necessita de uma abordagem multidisciplinar com uma assistência especializada em decorrência dos efeitos colaterais dos tratamentos. A quimioterapia e o transplante de células tronco mostram resultados com maiores taxas de recidiva. No entanto, a imunoterapia CAR-T cell tem mostrado resultados eficientes e promissores causando uma perspectiva importante na sobrevida da LLA.

show abstract

Section: Referencial Teóricounclassified

See 1 more Smart Citation

Tratamento da leucemia linfóide aguda em crianças: uma revisão narrativa

Weber¹,

Carrijo²,

Pereira³

et al. 2023

Braz. J. Develop.

View full text Add to dashboard Cite

show abstract

“…Several clinical trials have been performed to evaluate the efficacy of different CAR-T cells in different types of DSCs. Compared to hematological malignancies, target antigens are more diversified in different types of solid tumors, thereby creating heterogeneous treatment patterns for CAR-T therapy, and various responses have occurred in different clinical studies ( 19 ). Moreover, tumor antigens expressed on solid tumors can also be produced by normal tissue.…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, tumor antigens expressed on solid tumors can also be produced by normal tissue. When targeting antigens in normal tissue, CAR-T cell therapy will cause side effects depending on which organs or tissues are involved, resulting in discrepancies in the types of adverse effects shown in different clinical studies that use CAR-T cells to treat solid tumors in a variety of organs and tissues ( 19 , 20 ).…”

Section: Introductionmentioning

confidence: 99%

The efficacy and safety of chimeric antigen receptor T cells in digestive system cancers: a systematic review and meta-analysis

Zhao¹,

Zhang²,

Bian³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background As a successful treatment for hematological malignancy, chimeric antigen receptor T cells (CAR-T cells) have been expanded to solid tumors to demonstrate their safety and efficacy, especially for digestive system cancer (DSC). Various CAR-T cell constructs used in different types of DSCs result in heterogeneous responses. Thus, we aimed to systematically summarize the clinical response of DSCs treated with CAR-T cells and investigate factors associated with heterogeneity in outcomes. Methods Clinical studies of DSC patients treated with CAR-T cell therapy were selected from the PubMed, Cochrane, Embase, Web of Science databases before October 1, 2020. “CAR-T cell”, “solid tumor” and their synonymous terms were used to construct the search strategy. Duplicates, reviews, non-English literature, articles not related to clinical studies or CAR-T cells used for digestive tumors were excluded. The included studies were assessed by the Institute of Health Economics (IHE) risk of bias tool to check the methodological quality. The inverse variance method was used to perform data pooling and subgroup analysis to clarify the causes of heterogeneity. Publication bias was examined by funnel plots and Egger’s test. Results Twelve studies were included, and the risk of bias evaluation was demonstrated as plots using Review Manager 5.3. The pooled overall response rate (ORR) was 2% (95% CI: 0–6%), and the clinical benefit rate (CBR) was 42% (95% CI: 24–61%). According to subgroup analysis, costimulation (P=0.0449), lymphodepletion (P=0.0002), persistence of CAR-T cells (P=0.0443) and transduction method (P=0.0165) were factors contributing to heterogeneity. For adverse effects, pyrexia was the most frequent (35%, 95% CI: 24–61%). No publication bias was found, and the major results were robust within a slight fluctuation for each removal of one of the 12 studies. Discussion CAR-T cell therapy is generally beneficial for patients with DSCs though the ORR was still poor. Modified construction with more specific tumor antigens, costimulatory domain and lentiviral vectors is necessary to obtain a better antitumor response of CAR-T cell therapy. Information of survival data are needed for a more comprehensive analysis.

show abstract

Associação Brasileira de Hematologia, Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Review article: Cell therapy in solid tumors

Cited by 2 publications

References 61 publications

Tratamento da leucemia linfóide aguda em crianças: uma revisão narrativa

Tratamento da leucemia linfóide aguda em crianças: uma revisão narrativa

The efficacy and safety of chimeric antigen receptor T cells in digestive system cancers: a systematic review and meta-analysis

Contact Info

Product

Resources

About